<DOC>
	<DOC>NCT00397553</DOC>
	<brief_summary>To provide local data on efficacy and safety of insulin glulisine in patients with Type 1 Diabetes Mellitus receiving insulin glargine as basic insulin therapy</brief_summary>
	<brief_title>Insulin Glulisine, Diabetes Mellitus Type 1</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diabetes mellitus, Type 1 HbA1c 6.511.0% BMI &lt;35 kg/mÂ² Diabetes mellitus, Type 2 The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>